Evidence map›Paper›PMID 38892484›Full record

Trial reportNutrients2024

Effect of Methylfolate, Pyridoxal-5'-Phosphate, and Methylcobalamin (Soloways

Evgeny Pokushalov, Andrey Ponomarenko, Sevda Bayramova, Claire Garcia, Inessa Pak, Evgenya Shrainer, Marina Ermolaeva, Dmitry Kudlay, Michael Johnson, Richard Miller

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06163443 (Evaluating the Impact of B Vitamin Supplementation), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06163443 nacompletednot on this map

Evaluating the Impact of B Vitamin Supplementation (Soloways™) on Homocysteine and LDL-C Levels in Patients With MTHFR, MTR, and MTRR Polymorphisms: A Randomized, Double-blind, Placebo-controlled Trial

TypeinterventionalSponsorS.LAB (SOLOWAYS)Ran2022 to 2023Enrolled54ConditionsHyperhomocysteinemia, HyperlipoproteinemiasArmsVitamin B, Placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Genotype Combinations and Genetic Risk Score Analyses ofCurrent issues in molecular biology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Evgeny PokushalovCenter for New Medical Technologies, 630090 Novosibirsk, Russia.ORCID 0000-0002-9494-4234
Andrey PonomarenkoCenter for New Medical Technologies, 630090 Novosibirsk, Russia.ORCID 0000-0002-5468-9961
Sevda BayramovaCenter for New Medical Technologies, 630090 Novosibirsk, Russia.
Claire GarciaScientific Research Laboratory, Triangel Scientific, San Francisco, CA 94101, USA.
Inessa PakCenter for New Medical Technologies, 630090 Novosibirsk, Russia.
Evgenya ShrainerCenter for New Medical Technologies, 630090 Novosibirsk, Russia.ORCID 0000-0002-9675-3044
Marina ErmolaevaCenter for New Medical Technologies, 630090 Novosibirsk, Russia.
Dmitry KudlayInstitute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia.ORCID 0000-0003-1878-4467
Michael JohnsonScientific Research Laboratory, Triangel Scientific, San Francisco, CA 94101, USA.
Richard MillerScientific Research Laboratory, Triangel Scientific, San Francisco, CA 94101, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exploring the link between genetic polymorphisms in folate metabolism genes (MTHFR, MTR, and MTRR) and cardiovascular disease (CVD), this study evaluates the effect of B vitamin supplements (methylfolate, pyridoxal-5'-phosphate, and methylcobalamin) on homocysteine and lipid levels, potentially guiding personalized CVD risk management. In a randomized, double-blind, placebo-controlled trial, 54 patients aged 40-75 with elevated homocysteine and moderate LDL-C levels were divided based on MTHFR, MTR, and MTRR genetic polymorphisms. Over six months, they received either a combination of methylfolate, P5P, and methylcobalamin, or a placebo. At the 6 months follow-up, the treatment group demonstrated a significant reduction in homocysteine levels by 30.0% (95% CI: -39.7% to -20.3%) and LDL-C by 7.5% (95% CI: -10.3% to -4.7%), compared to the placebo (

Indexed as

5-Methyltetrahydrofolate-Homocysteine S-MethyltransferaseCholesterol, LDLDietary SupplementsFerredoxin-NADP ReductaseHomocysteineMethylenetetrahydrofolate Reductase (NADPH2)Pyridoxal PhosphateTetrahydrofolatesVitamin B 12AdultAgedDouble-Blind MethodFemaleHumansMaleMiddle Aged5-methyltetrahydrofolate5-Methyltetrahydrofolate-Homocysteine S-MethyltransferaseCholesterol, LDLFerredoxin-NADP ReductaseHomocysteinemecobalaminmethionine synthase reductaseMethylenetetrahydrofolate Reductase (NADPH2)MTHFR protein, humanMTR protein, humanPyridoxal PhosphateTetrahydrofolatesVitamin B 12Vitamin B Complexcardiovascular healthhomocysteineLDL-CmethylcobalaminmethylfolateMTHFRMTRMTRR polymorphismspersonalized medicinepyridoxal-5′-phosphatetriglycerides

Identifiers

PMID38892484
PMCPMC11173557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.